Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Median Technologies's 9-Day RSI or its related term are showing as below:
XPAR:ALMDT's 9-Day RSI is ranked better than 88.77% of 864
companies
in the Medical Devices & Instruments industry
Industry Median: 43.115
vs XPAR:ALMDT: 36.13
Median Technologies (XPAR:ALMDT) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Median Technologies 9-Day RSI Related Terms
XPAR:ALMDT vs ABT, SYK, MDT: 9-Day RSI Comparison
For the Medical Devices subindustry, Median Technologies's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Median Technologies 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Median Technologies's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Median Technologies's 9-Day RSI falls into.
Median Technologies (XPAR:ALMDT) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Median Technologies (XPAR:ALMDT) has a 9-Day RSI of 36.13 as of Jul. 27, 2026. According to the industry distribution chart, Median Technologies ranks #97 out of 864 companies in the Medical Devices & Instruments industry, placing it in the top 11.2%.
Is Median Technologies' 9-Day RSI too high?
Median Technologies' current 9-Day RSI is 36.13. The Medical Devices & Instruments industry median 9-Day RSI is 43.12. Median Technologies' value of 36.13 is 16.2% below this industry median. Based on the distribution chart, Median Technologies ranks #97 out of 864 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Median Technologies has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Median Technologies' 9-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Median Technologies ranks #97 out of 864 companies for 9-Day RSI. This places Median Technologies in the top 11% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 43.12. Median Technologies' value of 36.13 is 16.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 43.12, based on 864 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Median Technologies's current 9-Day RSI of 36.13 is 16.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 43.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Median Technologies's current 9-Day RSI is 36.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Median Technologies stock overvalued right now?
Based on GuruFocus' analysis, Median Technologies (XPAR:ALMDT) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.72, compared to a current price of €4.12 — trading 139.2% above its estimated fair value. The current 9-Day RSI is 36.13 and 16.2% below the Medical Devices & Instruments industry median of 43.12. Median Technologies' overall GF Score™ is 48/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Median Technologies (XPAR:ALMDT), the current 9-Day RSI is 36.13 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Median Technologies (XPAR:ALMDT) Overvalued in 2026?
Based on GuruFocus' analysis, Median Technologies stock appears to be overvalued.
The current stock price of €4.12 is trading 139.2% above its estimated GF Value™ of €1.72.
GuruFocus considers Median Technologies to be Significantly Overvalued.
Key valuation signals for XPAR:ALMDT:
9-Day RSI: 36.13
GF Value™: €1.72 vs. price of €4.12 (139.2% above fair value)
Industry Position: 16.2% below the Medical Devices & Instruments median (#97 of 864)
No single metric tells the full story. See the XPAR:ALMDT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The company focuses on the oncology clinical trials market and the cancer patient care market. The company has two platforms, iSee for imaging services in clinical trials and eyonis for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer. Its revenue is generated from contracts for providing imaging services for oncology clinical trials using dedicated software. Geographically, the company generates revenue from EMEA, the USA/Canada, and China.
48GF Score
Get the complete analysis for XPAR:ALMDT
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALMDT has been successfully added to your 
